Phase 2CompletedAge-related condition
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration
- Sponsor
- Kyowa Kirin Co., Ltd. (Industry)
- Enrolment
- 170 enrolled
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- KHK4951; Aflibercept Injection
- Ages
- adults, older adults
- Registry
- NCT06116890
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Primary outcomes
- Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline
History
Last registry update
Study completion
Primary completion
Started
Registered